SEC Company Response from Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — Aug 6, 2018
Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: Aug. 6, 2018 · CIK: 0001506251 · Accession: 0001213900-18-010295
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Citius Pharmaceuticals, Inc.
August 6, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1 (Registration No. 333- 226395)
Concurrence in Acceleration Request
Ladies and Gentlemen:
H.C. Wainwright & Co., LLC (“Wainwright”), as underwriter for the referenced offering, hereby concurs in the request by Citius Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on August 8, 2018, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly
yours,
H.C.
WAINWRIGHT & CO., LLC
Show Raw Text
CORRESP
1
filename1.htm
August
6, 2018
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Re:
Citius
Pharmaceuticals, Inc.
Registration Statement
on Form S-1 (Registration No. 333- 226395)
Concurrence in
Acceleration Request
Ladies
and Gentlemen:
H.C.
Wainwright & Co., LLC (“Wainwright”), as underwriter for the referenced offering, hereby concurs in the
request by Citius Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated
to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on August 8, 2018, pursuant to Rule 461 under the Securities
Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly
yours,
H.C.
WAINWRIGHT & CO., LLC
By:
/s/
Mark W. Viklund
Name:
Mark W. Viklund
Title: Chief Executive Officer